Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 13/20 | 0.41 |
| ▸ | AKT2 | P31751 | 10/20 | 0.40 |
| ▸ | TACR3 | P29371 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 4/20 | 0.37 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | FECH | P22830 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12133126 | 0.88 | AKT1 (0.46) | AKT1AKT2TACR3PDE2A | |
| SCHEMBL3786179 | 0.83 | AKT1 (0.38) | AKT1AKT2TACR3PDE2ASCN9A | |
| SCHEMBL1352355 | 0.80 | AKT1 (0.38) | AKT1AKT2AKT3FECH | |
| SCHEMBL12506640 | 0.78 | AKT1 (0.45) | AKT1AKT2TACR3PDE2ASCN9A | |
| SCHEMBL3776186 | 0.78 | ADORA1 (0.37) | AKT1 | |
| SCHEMBL2025815 | 0.77 | AKT1 (0.45) | AKT1AKT2TACR3AKT3FECH | |
| SCHEMBL12506520 | 0.77 | AKT1 (0.47) | AKT1AKT2TACR3AKT3 | |
| SCHEMBL3854158 | 0.76 | AKT1 (0.45) | AKT1AKT2TACR3AKT3SCN9A | |
| SCHEMBL12506551 | 0.76 | AKT1 (0.41) | AKT1AKT2TACR3PDE2ASCN9A | |
| SCHEMBL3710730 | 0.76 | ADK (0.55) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391623-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010088177-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-08-05 | — | — | WO | disclosed |